Cervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccination

Abstract

We aimed to assess the cervical cancer burden and performance of screening programme over the last decade in Apulia, Italy. Data from Hospital Discharge, Causes of Death and of Outpatient Services registries were analysed to estimate the disease burden, and data collected by the screening information system were used to evaluate the performance of the programme. We computed annual hospitalisation, incidence and mortality rates and number of outpatient services prescriptions for the follow‐up of preneoplastic/neoplastic lesions. Indicators as proposed by the National Centre for Screening Monitoring were computed to describe the screening performance. Hospitalisation rates declined from 47 in 2001 to 28 per 100,000 in 2014, incidence from 10.3 in 2004 to 6.0 per 100,000 in 2014 and mortality from 1.4 in 2001 to 1.0 per 100,000 in 2010. Prescriptions increased from 3,333 in 2006 to 4,968 in 2010, then decreased to 3,634/year in 2012–2014. Actual extension of screening increased from 10.8% in 2007 to 62% in 2014; compliance with the invitation was 32%/year. In the last decade, we observed a reduction in the cervical cancer burden as early effect of screening implementation.

Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007–2018)

“…The committee indicated the 12-year old female cohort as priority with the possible extension to the 25/26-year old female cohort [ 4 ]. From 2008, Italian Regions implemented the HPV vaccination program in the 12-year old female cohort and some of them extended free catch-up vaccination to one or more older cohorts (16- year old, 18-year old, and 25-year old cohorts) [ 5 ].…”

Comparison of cardiovascular disease and cancer prevalence between Mediterranean and north European middle-aged populations (The Cilento on Ageing Outcomes Study and The Malmö Offspring Study)

“…An additional source of bias that could contribute to the markedly higher prevalence of cancer in Cilento than in Malmö would be more active and frequent screening for cancer in Malmö than in Cilento. National screening for breast and cervical cancer in women is long since routine in both Italy and Sweden, whereas none of the two countries had national programs for prostate cancer screening at that time [23][24][25][26]. This strongly argues against differences in cancer screening routines as an explanation for the threefold higher prevalence of cancer in Malmö as compared to Cilento.…”

Role of different polyphenols in the treatment of cancer disease

“…Cervical cancer is the fourth most common among women and the second leading cause of death in women aged between 15-44. It is the first malignant neoplasm recognised by world health organisation which occurs exclusively by viral infection (Cappelli et al, 2018). Recent global studies estimates 527624 new cases with 265672 deaths due to cervical cancer annually with highest rate of incidence in eastern Africa (Zimbabwe) and lowest in western Asia (Shrestha et al, 2018).…”